Insight Molecular Diagnostics (IMDX) AI Stock Analysis

• Market Cap: $175.44M
• Dividend Yield: N/A
• Average Volume (3M): 42.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: 520.87%
• EPS Growth: 36.11%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 28,619,750
• 10 Day Avg. Volume: 47,668
• 30 Day Avg. Volume: 42,754
• PEG Ratio: -0.02
• Price to Book (P/B): -2.53
• Price to Sales (P/S): 16.54
• P/FCF Ratio: -1.47
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 17.22
• Enterprise Value/Gross Profit: 31.46
• Enterprise Value/Ebitda: -1.30
• 1Y Price Target: $8.50
• Price Target Upside: 59.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $5.50 ▲(3.00% Upside)

Insight Molecular Diagnostics' overall stock score is primarily impacted by its financial performance, which shows significant challenges in profitability, leverage, and cash flow management. While the earnings call provided a positive outlook with strategic initiatives and effective cash management, the technical analysis and valuation metrics reflect ongoing concerns. The company's ability to achieve FDA approval and improve financial metrics will be crucial for future performance.

Positive Factors

Product Development

The nearing FDA submission for GraftAssure DX highlights significant progress in product development, which can enhance market competitiveness and drive future revenue growth.

Cash Management

Maintaining a strong cash position and no debt indicates effective financial management, providing stability and flexibility for future investments and operations.

Market Expansion

A large TAM exceeding $1 billion suggests significant growth opportunities in the market, positioning the company to capture substantial market share with its innovative solutions.

Negative Factors

Profitability Challenges

Persistent negative profit margins indicate ongoing challenges in achieving profitability, which could hinder long-term financial sustainability and investment capacity.

High Leverage

High leverage poses financial risks and limits flexibility, potentially impacting the company's ability to invest in growth initiatives or weather economic downturns.

Cash Flow Concerns

Negative cash flow metrics highlight liquidity concerns, which could affect the company's ability to fund operations and strategic initiatives without additional financing.

Insight Molecular Diagnostics Business Overview & Revenue Model

Company Description

Insight Molecular Diagnostics (IMDX) is a biotechnology company specializing in the development and commercialization of advanced molecular diagnostic tests. Focused on the healthcare sector, IMDX leverages cutting-edge technologies to provide innovative solutions for precision medicine, particularly in oncology and infectious diseases. The company's core products include proprietary testing platforms that offer rapid and accurate genomic analysis, enabling healthcare professionals to make informed decisions based on patients' molecular profiles.

How the Company Makes Money

IMDX generates revenue primarily through the sale of its molecular diagnostic tests and related services to healthcare providers and laboratories. Key revenue streams include direct sales of test kits, licensing agreements for its proprietary technology, and collaborations with pharmaceutical companies for companion diagnostics. Additionally, the company may benefit from strategic partnerships with healthcare organizations that facilitate access to a broader customer base. As the demand for personalized medicine continues to grow, IMDX's innovative testing solutions position it well within a lucrative market.

Insight Molecular Diagnostics Financial Statement Overview

Summary

Insight Molecular Diagnostics faces significant financial challenges. Despite some revenue growth and a strong gross profit margin, the company struggles with profitability, high leverage, and negative cash flows. These issues indicate potential financial instability and highlight the need for strategic financial restructuring and improved operational efficiency.

Income Statement

Insight Molecular Diagnostics shows a mixed performance in its income statement. The company has achieved revenue growth, with a TTM revenue growth rate of 3.41%. However, profitability remains a significant concern, as evidenced by negative net profit margins (-14.90%) and EBIT margins (-14.87%). The gross profit margin is relatively healthy at 63.42%, indicating efficient cost management in production. Despite these strengths, the persistent negative net income highlights ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet of Insight Molecular Diagnostics reveals financial instability. The company has a high debt-to-equity ratio of 3.07, indicating significant leverage and potential financial risk. The negative stockholders' equity suggests potential solvency issues. Return on equity is also negative, reflecting the company's inability to generate profits from its equity base. These factors highlight the need for improved financial management and capital structure optimization.

Cash Flow

The cash flow statement indicates challenges in cash generation. The company has a negative operating cash flow, and the free cash flow growth rate is declining at -6.29%. However, the free cash flow to net income ratio is slightly positive at 1.01, suggesting that the company is managing to convert some of its net income into free cash flow. Despite this, the overall negative cash flow metrics highlight liquidity concerns and the need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.40M	1.88M	1.50M	958.00K	2.20M	1.22M
Gross Profit	2.41M	740.00K	413.00K	-18.00K	1.42M	-639.00K
EBITDA	-58.47M	-59.02M	-23.12M	-13.31M	-48.46M	-30.54M
Net Income	-60.78M	-60.66M	-27.78M	-72.90M	-64.10M	-29.93M
Balance Sheet
Total Assets	43.94M	35.08M	74.89M	100.09M	159.56M	55.42M
Cash, Cash Equivalents and Short-Term Investments	18.69M	8.64M	9.43M	20.43M	33.85M	7.82M
Total Debt	3.13M	3.66M	2.87M	3.54M	5.68M	8.63M
Total Liabilities	53.13M	47.35M	54.42M	60.50M	94.35M	21.94M
Stockholders Equity	-9.20M	-12.27M	20.47M	39.59M	65.22M	33.48M
Cash Flow
Free Cash Flow	-23.91M	-21.23M	-23.61M	-49.91M	-38.19M	-27.21M
Operating Cash Flow	-21.99M	-20.71M	-23.32M	-45.57M	-35.94M	-25.98M
Investing Cash Flow	-1.92M	-512.00K	-932.00K	-4.34M	-13.96M	-11.75M
Financing Cash Flow	39.16M	20.43M	12.19M	35.81M	78.36M	22.80M

Insight Molecular Diagnostics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.34
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMDX, the sentiment is Neutral. The current price of 5.34 is below the 20-day moving average (MA) of 6.48, below the 50-day MA of 5.43, and above the 200-day MA of 3.59, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 6.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMDX.

Insight Molecular Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMDX	47 Neutral	$175.44M	-1.76	-9999.00%	―	520.87%	36.11%
MGNX	45 Neutral	$89.83M	―	-81.13%	―	-9.70%	23.23%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
ELUT	42 Neutral	$39.00M	-0.87	―	―	-14.92%	72.81%
ATOS	36 Underperform	$109.55M	-3.77	-48.89%	―	―	-9.42%

Insight Molecular Diagnostics Corporate Events

OncoCyte Corp’s Earnings Call: Progress Amid Challenges

The recent earnings call for OncoCyte Corp showcased a generally positive sentiment, highlighting significant advancements in product development and financial stability. However, the company faces challenges due to the government shutdown and slower-than-expected clinical trial enrollment, which could impact their timeline for regulatory approvals.

Insight Molecular Diagnostics Reports Q3 2025 Progress

Insight Molecular Diagnostics Inc. (iMDx) is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes, particularly in the organ transplant sector.

Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study

Study Overview: The GraftAssureDx Study, officially titled ‘Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring,’ aims to determine if the dd-cfDNA test can effectively assess rejection in kidney transplant recipients. This study is significant as it could offer a less invasive alternative to standard graft biopsies, potentially improving patient outcomes and monitoring efficiency.

Insight Molecular Diagnostics Extends Executive Employment Agreement

On September 28, 2025, Insight Molecular Diagnostics Inc. granted stock options to key executives under its Amended and Restated 2018 Equity Incentive Plan, with options vesting over three years. Additionally, on September 29, 2025, the company amended Dr. Ekkehard Schütz’s employment agreement to extend its term indefinitely until termination under existing terms.

The most recent analyst rating on (IMDX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Insight Molecular Diagnostics stock, see the IMDX Stock Forecast page.

Insight Molecular Diagnostics Approves Executive Salary Increases

On September 16, 2025, Insight Molecular Diagnostics Inc. announced that its Board of Directors approved salary increases for key executives. The President and CEO, Joshua Riggs, will see his salary rise from $420,000 to $520,000, while the CFO, Andrea James, will have her salary increased from $341,250 to $441,250, effective September 15, 2025.

The most recent analyst rating on (IMDX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Insight Molecular Diagnostics stock, see the IMDX Stock Forecast page.

OncoCyte Corp’s Earnings Call: Progress Amid Challenges

The recent earnings call for OncoCyte Corp reflects a company making notable strides in its FDA submission process and assay improvements, buoyed by strong engagement with transplant centers and a significant achievement in positive predictive value. Despite these advancements, the company faces challenges in revenue generation and clinical trial enrollment.